Other Name
Sponsor Type
United States
Grant Types
Research Project Workshop/Conference Collaboration/Cooperative Agreement
 Contact Info
10903 New Hampshire Avenue, Silver Spring, MD 20993-0002
Last modified on 2020-01-30 00:43:07
The Center for Biologics Evaluation and Research (CBER) is one Center within the Food and Drug Administration, an Agency within the United States Government's Department of Health and Human Services (HHS). CBER's mission is to protect and enhance the public health through the regulation of biological and related products including blood, vaccines, allergenics, tissues, and cellular and gene therapies. Biologics, in contrast to drugs that are chemically synthesized, are derived from living sources (such as humans, animals, and microorganisms), are not easily identified or characterized, and many are manufactured using biotechnology. These products often represent cutting-edge biomedical research and, in time, may offer the most effective means to treat a variety of medical illnesses and conditions that presently have few or no other treatment options. CBER's review of new biological products, and for new indications for already approved products, requires evaluating scientific and clinical data submitted by manufacturers to determine whether the product meets CBER's standards for approval. After a thorough assessment of the data, CBER makes a decision based on the risk-benefit for the intended population and the product's intended use. CBER's authority resides in the Public Health Service Act and in specific sections of the Food Drug and Cosmetic Act. Although medical products are required to be safe, safety does not mean zero risk, since all medical products are associated with some level of risk. A safe biological product is one that has reasonable risks, given the patient's condition, the magnitude of the benefit expected, and the alternatives available. The choice to use a biological product involves balancing the benefits to be gained with the potential risks. CBER is committed to a product approval process that maximizes the benefits and minimizes the risks to patients of the biological product. CBER is committed to providing up-to-date information to the public, healthcare professionals, the media and product manufacturers about the products CBER regulates through the Biologics Web pages. Site content is developed and reviewed by CBER staff prior to publication. VISION The Center for Biologics Evaluation and Research (CBER) uses sound science and regulatory expertise to: - Protect and improve public and individual health in the United States and, where feasible, globally; - Facilitate the development, approval of, and access to safe and effective products and promising new technologies; and - Strengthen CBER as a preeminent regulatory organization for biologics. MISSION The mission of the Center for Biologics Evaluation and Research (CBER) is to ensure the safety, purity, potency, and effectiveness of biological products including vaccines, allergenics, blood and blood products, and cells, tissues, and gene therapies for the prevention, diagnosis, and treatment of human diseases, conditions, or injury. Through our mission, we also seek to protect the public against the threats of emerging infectious diseases and bioterrorism.
Sponsor Relationship

  Center for Biologics Evaluation and Research is a part of:

  No sponsors in our database are part of Center for Biologics Evaluation and Research.

Most Recent Grants from This Sponsor
Funding Opportunity Number: RFA-FD-23-025 Background The Food and Drug Administration (FDA)...
Added on 2022-12-09T04:47:03Z
Funding Opportunity Number: PAR-23-072 The FDA recognizes the value of supporting high quality...
Added on 2022-12-04T05:36:54Z
Funding Opportunity Number: PAR-21-178 Drug development tools (DDTs) are methods, materials,...
Added on 2021-02-18T19:54:33Z
Deadline Approaching Grants
No grants from this sponsor have deadline within a month period.